Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Inhibition of CPT1A reverses AML1-ETO-induced differentiation blockage by activating BCL-2/MYC signaling and metabolic reprogramming

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYang LiuHWHaoren WangRGRunxia Gu

Discussion

Loading...

Member takes

Overview

Pharmacological CPT1A inhibition improves HSC function and metabolic activity in leukemic stem cells, suggesting a potential therapeutic approach.

Key Points

  • This research aims to explore the role of CPT1A in hematopoietic stem cells and its contribution to differentiation blockage in AML.
  • Evaluated CPT1A expression using ChIP-seq and verified in a U937 cell model
  • Performed pharmacological inhibition and CRISPR-Cas9 knockout of Cpt1a in AML models
  • Assessed HSPC populations and metabolic activity with flow cytometry
  • Conducted metabolomic profiling and RNA-seq analyses
  • CPT1A is overexpressed in leukemic stem and progenitor cells, associating with poor clinical outcomes
  • CPT1A inhibition reverses differentiation block and restores myeloid lineage in AML models
  • Metabolic reprogramming enhances glycolysis and OXPHOS coupling in response to CPT1A suppression

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5d4https://doi.org/10.1182/blood-2025-3224
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CPT1B promotes acute myeloid leukemia progression via fatty acid oxidation–dependent metabolic reprogramming2026
  2. 2Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Pre-leukemic Cells2024 · 7 citations
  3. 3APC/C-regulated CPT1C promotes tumor progression by upregulating the energy supply and accelerating the G1/S transition2024 · 11 citations
  4. 4RUNX1::ETO and CBFβ::MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core‐binding factor‐acute myeloid leukaemia2024 · 1 citations
  5. 5SLC25A1 reprograms mitochondrial and fatty acid metabolism to promote the progression of acute myeloid leukemia2025 · 4 citations